James William Rogers Sells 11,529 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) CFO James William Rogers sold 11,529 shares of the stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $55.00, for a total value of $634,095.00. Following the sale, the chief financial officer owned 114,866 shares in the company, valued at $6,317,630. The trade was a 9.12% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

James William Rogers also recently made the following trade(s):

• On Tuesday, May 19th, James William Rogers sold 10,853 shares of Tempus AI stock. The stock was sold at an average price of $44.07, for a total value of $478,291.71.

Tempus AI Stock Up 3.9%

NASDAQ TEM opened at $58.31 on Tuesday. The company has a quick ratio of 3.15, a current ratio of 3.31 and a debt-to-equity ratio of 2.96. The company has a fifty day moving average of $50.14 and a two-hundred day moving average of $54.80. The firm has a market capitalization of $10.47 billion, a price-to-earnings ratio of -33.90 and a beta of 3.64. Tempus AI, Inc. has a 52 week low of $41.73 and a 52 week high of $104.32.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.08. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The business had revenue of $348.12 million for the quarter, compared to analysts’ expectations of $345.44 million. During the same quarter in the previous year, the business posted ($0.24) earnings per share. The business’s revenue was up 36.1% compared to the same quarter last year. On average, analysts predict that Tempus AI, Inc. will post -1.35 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently commented on TEM shares. Jefferies Financial Group began coverage on shares of Tempus AI in a report on Monday, April 13th. They set an “underperform” rating and a $35.00 price target on the stock. BTIG Research reissued a “buy” rating and issued a $80.00 price objective on shares of Tempus AI in a research note on Monday, June 1st. Guggenheim dropped their target price on Tempus AI from $95.00 to $60.00 and set a “buy” rating for the company in a research report on Monday, March 30th. Morgan Stanley cut their target price on Tempus AI from $85.00 to $70.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 3rd. Finally, Wall Street Zen upgraded Tempus AI from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Nine investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Tempus AI has a consensus rating of “Moderate Buy” and a consensus price target of $68.54.

Institutional Trading of Tempus AI

A number of large investors have recently made changes to their positions in the stock. NewEdge Advisors LLC grew its holdings in shares of Tempus AI by 1.3% in the first quarter. NewEdge Advisors LLC now owns 42,996 shares of the company’s stock worth $1,944,000 after purchasing an additional 536 shares during the last quarter. Avidity Partners Management LP purchased a new position in Tempus AI in the 1st quarter worth about $1,130,000. Silverback Asset Management LLC lifted its holdings in Tempus AI by 44.5% during the 1st quarter. Silverback Asset Management LLC now owns 35,700 shares of the company’s stock valued at $1,614,000 after buying an additional 11,000 shares in the last quarter. Vestor Capital LLC lifted its holdings in Tempus AI by 338.2% during the 1st quarter. Vestor Capital LLC now owns 1,538 shares of the company’s stock valued at $70,000 after buying an additional 1,187 shares in the last quarter. Finally, Arkadios Wealth Advisors boosted its position in Tempus AI by 9.6% in the 1st quarter. Arkadios Wealth Advisors now owns 4,963 shares of the company’s stock valued at $224,000 after buying an additional 435 shares during the period. 24.22% of the stock is owned by hedge funds and other institutional investors.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.